Galectin Therapeutics Inc.

NasdaqCM:GALT Stock Report

Market Cap: US$80.3m

Galectin Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:GALT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Dec 24BuyUS$7,540Harold ShlevinIndividual6,500US$1.16
24 Dec 24BuyUS$8,134Kevin FreemanIndividual10,000US$0.81
24 Dec 24BuyUS$11,045Kary EldredIndividual13,469US$0.82
24 Dec 24BuyUS$8,164Richard ZordaniIndividual10,000US$0.82
23 Oct 24BuyUS$1,300Kary EldredIndividual500US$2.60
17 Oct 24BuyUS$3,432Kevin FreemanIndividual1,300US$2.64
16 Oct 24BuyUS$27,000Kevin FreemanIndividual10,000US$2.70
23 Aug 24BuyUS$8,050Richard ZordaniIndividual3,500US$2.30
22 Jul 24BuyUS$956Kary EldredIndividual400US$2.39
20 Jun 24BuyUS$5,950Kevin FreemanIndividual2,500US$2.38
30 Apr 24BuyUS$3,520Richard ZordaniIndividual1,000US$3.52
24 Apr 24BuyUS$3,390Joel LewisIndividual1,000US$3.39
23 Apr 24SellUS$76,50010x Capital Management, LLCCompany25,000US$3.06
22 Apr 24BuyUS$7,450Kevin FreemanIndividual2,500US$2.98

Insider Trading Volume

Insider Buying: GALT insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GALT?
Owner TypeNumber of SharesOwnership Percentage
Private Companies75,4320.12%
Hedge Funds5,922,2079.44%
Institutions9,826,58615.7%
Individual Insiders12,863,23920.5%
General Public34,074,36154.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 43.44% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.4%
Richard Uihlein
10,306,461US$13.2m0.1%no data
9.44%
10x Capital Management, LLC
5,922,207US$7.6m0%100.0%
3.4%
The Vanguard Group, Inc.
2,134,205US$2.7m0.86%no data
2.56%
BlackRock, Inc.
1,607,124US$2.1m2.77%no data
1.88%
Osaic Wealth, Inc. , Asset Management Arm
1,182,095US$1.5m5.16%no data
1.43%
Joel Lewis
899,012US$1.2m0%no data
1.37%
Geode Capital Management, LLC
862,542US$1.1m2.47%no data
1.22%
James Czirr
764,616US$978.7k0.75%no data
0.8%
Kary Eldred
499,634US$639.5k2.88%no data
0.77%
Commonwealth Equity Services, LLC
483,264US$618.6k-0.02%no data
0.63%
Wealthspire Advisors LLC
398,374US$509.9k0%no data
0.56%
Geneos Wealth Management, Inc., Asset Management Arm
352,935US$451.8k-10.4%0.02%
0.4%
State Street Global Advisors, Inc.
251,014US$321.3k9.32%no data
0.39%
Morgan Stanley, Investment Banking and Brokerage Investments
245,050US$313.7k11.6%no data
0.37%
Northern Trust Global Investments
234,280US$299.9k84.5%no data
0.33%
Atria Wealth Solutions, Inc.
207,100US$265.1k-3.13%no data
0.23%
Kevin Freeman
142,832US$182.8k17.5%no data
0.22%
Soltis Investment Advisors, LLC
140,750US$180.2k0%0.02%
0.18%
Cutter & Company, Inc., Asset Management Arm
115,488US$147.8k0%0.03%
0.18%
Cambridge Investment Research Advisors, Inc.
114,720US$146.8k2.31%no data
0.13%
Gilbert Omenn
82,240US$105.3k0%no data
0.13%
LPL Financial Corporation, Asset Management Arm
81,908US$104.8k-6.13%no data
0.13%
Susquehanna International Group, LLP, Asset Management Arm
81,467US$104.3k-59.7%no data
0.13%
Sanctuary Advisors, LLC
79,113US$101.3k-21.4%no data
0.12%
Cross Consulting and Services, LLC
75,432US$96.6k-85.2%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/16 07:15
End of Day Share Price 2025/01/16 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Galectin Therapeutics Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeAscendiant Capital Markets LLC
Mayank MamtaniB. Riley Securities, Inc.
Vernon BernardinoDawson James Securities